Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Christopher Major"'
Autor:
Songbai Wang, Mike Burgess, Christopher Major, Alistair English, Maranna Sweeney, Arndt Hartmann
Publikováno v:
The Journal of Pathology: Clinical Research, Vol 6, Iss 3, Pp 207-214 (2020)
Abstract Erdafitinib, a pan‐fibroblast growth factor receptor (FGFR) inhibitor received accelerated approval from the US Food and Drug Administration (FDA) for locally advanced or metastatic urothelial carcinoma (mUC) in adult patients with specifi
Externí odkaz:
https://doaj.org/article/5b71d872bc6740d1b167f4d9a6b1f1e9
Autor:
John Gerecitano, Jodi Carey, Christopher Major, Peter Johnson, Songbai Wang, Pier Luigi Zinzani, Wyndham H. Wilson, Steven Sun, Jessica Vermeulen, S. Martin Shreeve, Louis M. Staudt, Laurie H. Sehn, Michael Schaffer, Brendan P. Hodkinson, Sriram Balasubramanian
Publikováno v:
Br J Haematol
We assessed the concordance between immunohistochemistry (IHC) and gene expression profiling (GEP) for determining diffuse large B-cell lymphoma (DLBCL) cell of origin (COO) in the phase III PHOENIX trial of rituximab plus cyclophosphamide, doxorubic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1afbf43ebf161817ace05edf02704a79
https://doi.org/10.1111/bjh.17450
https://doi.org/10.1111/bjh.17450
Autor:
Fereshteh Ramezani, Christopher Major, Colter Barney, Justin Williams, Brock J. LaMeres, Bradley M. Whitaker
Publikováno v:
2022 Intermountain Engineering, Technology and Computing (IETC).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::494825ade17f45cf09083bf56c302122
https://doi.org/10.1109/ietc54973.2022.9796883
https://doi.org/10.1109/ietc54973.2022.9796883
Publikováno v:
Chemistry (Weinheim an der Bergstrasse, Germany). 28(27)
The known boranes (R(Me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::245941656e6d6e128edfaf86ed9b0f7d
https://pubmed.ncbi.nlm.nih.gov/35262980
https://pubmed.ncbi.nlm.nih.gov/35262980
Autor:
Christopher Major, Louis M. Staudt, P. Johnson, Brendan P. Hodkinson, Jessica Vermeulen, Jodi Carey, Michael Schaffer, M. Shreeve, Shean-Sheng Wang, Walter R. Wilson, Anas Younes, Steven Sun, Grace Liu, C. Loefgren, P. L. Zinzani, Laurie H. Sehn, Sen Hong Zhuang, Sriram Balasubramanian
Publikováno v:
Hematological Oncology. 37:140-142
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c6cf5a6d7658cfc5128085c73d961ff5
https://doi.org/10.1002/hon.99_2629
https://doi.org/10.1002/hon.99_2629
Autor:
Maranna Sweeney, Christopher Major, Mike Burgess, Alistair English, Arndt Hartmann, Songbai Wang
Publikováno v:
The Journal of Pathology: Clinical Research
The Journal of Pathology: Clinical Research, Vol 6, Iss 3, Pp 207-214 (2020)
The Journal of Pathology: Clinical Research, Vol 6, Iss 3, Pp 207-214 (2020)
Erdafitinib, a pan‐fibroblast growth factor receptor (FGFR) inhibitor received accelerated approval from the US Food and Drug Administration (FDA) for locally advanced or metastatic urothelial carcinoma (mUC) in adult patients with specific FGFR3/2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7465052cf876652fa8c8c59c68128a5
https://pubmed.ncbi.nlm.nih.gov/32304281
https://pubmed.ncbi.nlm.nih.gov/32304281
Autor:
Christopher Major
Publikováno v:
Art Therapy Practices for Resilient Youth ISBN: 9781315229379
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6caf706c69d97a5def65f0a5495d12ba
https://doi.org/10.4324/9781315229379-9
https://doi.org/10.4324/9781315229379-9
Autor:
Qi Xia, Christopher Major, Julie C. Switzky, Juergen E. Gschwend, Ben Tran, Morgan Rouprêt, James W.F. Catto, Yohann Loriot, Gary D. Steinberg, Siamak Daneshmand, Mahadi Baig, Joan Palou-Redorta, Ademi E. Santiago-Walker
Publikováno v:
Journal of Clinical Oncology. 38:TPS603-TPS603
TPS603 Background: ERDA, an oral pan-FGFR inhibitor, is approved by the US FDA for metastatic urothelial carcinoma (mUC) with susceptible FGFR3 or FGFR2 gene alterations and progressed on/ or after at least 1 line of prior platinum-containing chemoth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::88fe81eb702e6010185e2253714afa27
https://doi.org/10.1200/jco.2020.38.6_suppl.tps603
https://doi.org/10.1200/jco.2020.38.6_suppl.tps603
Publikováno v:
Journal of Legal Studies Education. 21:203-224
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8f6725f6cb665bb4c50a269a2e3a00dc
https://doi.org/10.1111/j.1744-1722.2004.tb00317.x
https://doi.org/10.1111/j.1744-1722.2004.tb00317.x
Publikováno v:
Molecular Pharmacology. 65:744-752
Clinically, there is a great need for small molecule inhibitors that could control pathogenic effects of transforming growth factor (TGF-beta) and/or modulate effects of TGF-beta in normal responses. Inhibition of TGF-beta signaling would be predicte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d85ecd80303917119b111a12f0753db
https://doi.org/10.1124/mol.65.3.744
https://doi.org/10.1124/mol.65.3.744